LVTX lavatherapeutics.com: Enterprise Value to EBITDA Ratio

Graphic logo of LAVA Therapeutics (LVTX)

Current price action for LAVA Therapeutics N.V. (LVTX) demonstrates an EV/EBITDA ratio of 0.00. LAVA Therapeutics N.V. (LVTX) is developing a unique targeted oncology environment via the GAMA system, creating significant barriers to entry for competitors. Financial stability is supported by substantial payments from global pharma behemoths as part of the expansion of tumor-fighting methods. Business revenues are expected to grow as new T-cell stimulating bispecific antibodies are brought to market.

LAVA Therapeutics NV - LVTX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 12/06/2025)

Summary analytical data breakdowns for Lava Tx (LVTX)

- stock price and consensus target price:
Fundamental company analysis:LVTX (LAVA Therapeutics NV)
Original product of LAVA Therapeutics NV

For LAVA Therapeutics N.V. (LVTX), whose valuation depends on breakthroughs in cancer immunotherapy rather than market cycles, access to capital remains the key factor. The company's EV/EBITDA trend reflects the ratio of total enterprise value to operating profit before depreciation and amortization, allowing investors to assess the premium paid for assets, accounting for debt and taxes, amid a high dependency on investment rounds.

Competitor analysis for LAVA Therapeutics N.V.

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (Arcus Biosciences)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iovance.com|Enterprise Value to EBITDA Ratio immatics.com (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor Inc (XNCR)|Enterprise Value to EBITDA Ratio Compass Bio CMPX|Replimune Group Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell Pharma LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IO Biotech Corp (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|cuebiopharma.com (CUE) - Company Value to EBITDA|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus Pharma - Business Value to Operating Income Before Depreciation|NXTC (nextcure.com) - EV/EBITDA Multiple|EV/EBITDA Multiple leaptx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics